Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans ; volume:20 ; number:03 ; year:2021 ; pages:324-326
World Journal of Nuclear Medicine ; 20, Heft 03 (2021), 324-326

Contributor: Amoui, Mahasti
Ahmadi, Reyhane
Qutbi, Mohsen
Asli, Isa Neshandar

DOI: 10.4103/wjnm.wjnm_35_21

URN: urn:nbn:de:101:1-2022051210381911398968

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Amoui, Mahasti
Ahmadi, Reyhane
Qutbi, Mohsen
Asli, Isa Neshandar

Other Objects (12)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Related objects

Reset password